Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study IV
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Immunochemotherapy.
- Who it may be relevant to
- Registry conditions: Lymphoma. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- South Korea
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Prospective Study for Patients With Lymphoma at the Samsung Medical Center
Overview
This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.
Detailed description
The study population is aggressive lymphomas requiring systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled into the study. Patients can be treated according to the principle of routine care of our institute. The study process is as follows.
1. Registration after informed consent. 2. Laboratory and radiological evaluation after registration including collection of serum and cell-free DNA from patients' peripheral blood 3. Interim and final response evaluation including collection of serum and cell-free DNA from patients' peripheral blood 4. Regular monitoring disease status and update of survival status 5. Laboratory and radiological evaluation after relapse or progression including collection of serum and cell-free DNA from patients' peripheral blood
Interventions
- Drug Immunochemotherapy
Systemic chemotherapy with curative intent
Primary outcome measures
- Reponse rate [Time frame: 3 months after the completion of treatment]
- Response [Time frame: 3 months after chemotherapy]
Eligibility criteria
Inclusion criteria
- Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas
- 20 years
- Patients requiring systemic chemotherapy with curative intent
- Written informed consent
Exclusion criteria
- Myeloid malignancy
- Multiple myeloma
- Patients do not require systemic chemotherapy with curative intent
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
South Korea · 1 center
- Samsung Medical Center — Seoul
Identifiers
NCT: NCT07032103 · SMC-Lym-IV